By Colin Kellaher
Baxter International has reduced its dividend by 41% ahead of the medical-products maker's planned $3.8 billion sale of its kidney-care segment to Carlyle Group.
Baxter late Monday said its board declared a quarterly dividend of 17 cents, down from the 29-cent rate the Deerfield, Ill., company had been paying.
The new payout, equal to 68 cents a year, represents an annual yield just under 2% based on Monday's closing price of $34.22, down from 3.39% previously.
Baxter early last year said it created a standalone kidney-care company as part of a broader realignment, and in August signed a deal to sell the unit to Carlyle, with a closing expected in late 2024 or early 2025.
Baxter, which previously said it would use the roughly $3 billion in after-tax cash proceeds from the deal to pare its debt load, said the new dividend rate targets a payout ratio of about 25% of adjusted earnings, which the company said is in line with its peers.
Baxter said the reduced dividend is payable Jan. 2 to shareholders of record Nov. 29.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
November 12, 2024 06:36 ET (11:36 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。